Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Early-life microbiota exposure restricts myeloid-derived suppressor cell-driven colonic tumorigenesis.

Harusato A, Viennois E, Etienne-Mesmin L, Matsuyama S, Abo H, Osuka S, Lukacs NW, Naito Y, Itoh Y, Li JD, Merlin D, Gewirtz AT, Denning TL.

Cancer Immunol Res. 2019 Feb 19. pii: canimm.0444.2018. doi: 10.1158/2326-6066.CIR-18-0444. [Epub ahead of print]

PMID:
30782668
2.

Oral Gavage of Ginger Nanoparticle-Derived Lipid Vectors Carrying Dmt1 siRNA Blunts Iron Loading in Murine Hereditary Hemochromatosis.

Wang X, Zhang M, Flores SRL, Woloshun RR, Yang C, Yin L, Xiang P, Xu X, Garrick MD, Vidyasagar S, Merlin D, Collins JF.

Mol Ther. 2019 Jan 12. pii: S1525-0016(19)30006-1. doi: 10.1016/j.ymthe.2019.01.003. [Epub ahead of print]

3.

Overexpression of CD98 in intestinal epithelium dysregulates miRNAs and their targeted proteins along the ileal villus-crypt axis.

Han MK, Baker M, Zhang Y, Yang C, Zhang M, Garg P, Viennois E, Merlin D.

Sci Rep. 2018 Nov 1;8(1):16220. doi: 10.1038/s41598-018-34474-9.

4.

TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis.

Xiao B, Chen Q, Zhang Z, Wang L, Kang Y, Denning T, Merlin D.

J Control Release. 2018 Oct 10;287:235-246. doi: 10.1016/j.jconrel.2018.08.021. Epub 2018 Aug 11.

PMID:
30107214
5.

Advances in Plant-derived Edible Nanoparticle-based lipid Nano-drug Delivery Systems as Therapeutic Nanomedicines.

Yang C, Zhang M, Merlin D.

J Mater Chem B. 2018 Mar 7;6(9):1312-1321. doi: 10.1039/C7TB03207B. Epub 2018 Jan 29.

PMID:
30034807
6.

Purification of Total RNA from DSS-treated Murine Tissue via Lithium Chloride Precipitation.

Viennois E, Tahsin A, Merlin D.

Bio Protoc. 2018 May 5;8(9). pii: e2829. doi: 10.21769/BioProtoc.2829.

7.

Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer.

Xiao B, Viennois E, Chen Q, Wang L, Han MK, Zhang Y, Zhang Z, Kang Y, Wan Y, Merlin D.

ACS Nano. 2018 Jun 8. doi: 10.1021/acsnano.7b08499. [Epub ahead of print]

PMID:
29860836
8.

Nanoparticle-Based Oral Drug Delivery Systems Targeting the Colon for Treatment of Ulcerative Colitis.

Zhang M, Merlin D.

Inflamm Bowel Dis. 2018 Jun 8;24(7):1401-1415. doi: 10.1093/ibd/izy123.

PMID:
29788186
9.

A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage.

Ngo VL, Abo H, Maxim E, Harusato A, Geem D, Medina-Contreras O, Merlin D, Gewirtz AT, Nusrat A, Denning TL.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5076-E5085. doi: 10.1073/pnas.1718902115. Epub 2018 May 14.

10.

Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease.

Viennois E, Pujada A, Zen J, Merlin D.

Compr Physiol. 2018 Mar 25;8(2):731-760. doi: 10.1002/cphy.c170032.

PMID:
29687900
11.

Oral delivery of curcumin via porous polymeric nanoparticles for effective ulcerative colitis therapy.

Chen Q, Si X, Ma L, Ma P, Hou M, Bai S, Wu X, Wan Y, Xiao B, Merlin D.

J Mater Chem B. 2017 Aug 7;5(29):5881-5891. doi: 10.1039/C7TB00328E. Epub 2017 May 5.

12.
13.

iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.

Ma L, Chen Q, Ma P, Han MK, Xu Z, Kang Y, Xiao B, Merlin D.

Nanomedicine (Lond). 2017 Aug;12(16):1991-2006. doi: 10.2217/nnm-2017-0107. Epub 2017 Jul 26.

14.

Protein secondary structure analysis of dried blood serum using infrared spectroscopy to identify markers for colitis screening.

Titus J, Ghimire H, Viennois E, Merlin D, Unil Perera AG.

J Biophotonics. 2018 Mar;11(3). doi: 10.1002/jbio.201700057. Epub 2017 Sep 12.

PMID:
28742273
15.

Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis.

Zhang M, Wang X, Han MK, Collins JF, Merlin D.

Nanomedicine (Lond). 2017 Aug;12(16):1927-1943. doi: 10.2217/nnm-2017-0196. Epub 2017 Jun 30.

16.

Serum miRNA signature diagnoses and discriminates murine colitis subtypes and predicts ulcerative colitis in humans.

Viennois E, Zhao Y, Han MK, Xiao B, Zhang M, Prasad M, Wang L, Merlin D.

Sci Rep. 2017 May 31;7(1):2520. doi: 10.1038/s41598-017-02782-1.

PMID:
28566745
Free PMC Article
17.

MiRNA Quantitation with Microelectrode Sensors Enabled by Enzymeless Electrochemical Signal Amplification.

Wang T, Wang G, Merlin D, Viennois E.

Methods Mol Biol. 2017;1580:249-263. doi: 10.1007/978-1-4939-6866-4_17.

PMID:
28439838
18.

Nanotherapeutics for the treatment of inflammatory bowel disease.

Chen Q, Xiao B, Merlin D.

Expert Rev Gastroenterol Hepatol. 2017 Jun;11(6):495-497. doi: 10.1080/17474124.2017.1309282. Epub 2017 Mar 24. No abstract available.

PMID:
28317404
19.

Low-frequency ultrasound may improve drug penetration in colonic mucosa.

Chen Q, Xiao B, Merlin D.

Transl Cancer Res. 2017 Mar;6(Suppl 2):S276-S279. doi: 10.21037/tcr.2017.03.62. No abstract available.

20.

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D.

Mol Ther. 2017 Jul 5;25(7):1628-1640. doi: 10.1016/j.ymthe.2016.11.020. Epub 2017 Jan 28.

21.

Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation.

Xiao B, Zhang Z, Viennois E, Kang Y, Zhang M, Han MK, Chen J, Merlin D.

Theranostics. 2016 Sep 25;6(12):2250-2266. eCollection 2016.

22.

Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages.

Xiao B, Ma P, Ma L, Chen Q, Si X, Walter L, Merlin D.

J Colloid Interface Sci. 2017 Mar 15;490:520-528. doi: 10.1016/j.jcis.2016.11.088. Epub 2016 Nov 26.

23.

Dietary Emulsifier-Induced Low-Grade Inflammation Promotes Colon Carcinogenesis.

Viennois E, Merlin D, Gewirtz AT, Chassaing B.

Cancer Res. 2017 Jan 1;77(1):27-40. doi: 10.1158/0008-5472.CAN-16-1359. Epub 2016 Nov 7.

24.

Do ginger-derived nanoparticles represent an attractive treatment strategy for inflammatory bowel diseases?

Zhang M, Collins JF, Merlin D.

Nanomedicine (Lond). 2016 Dec;11(23):3035-3037. Epub 2016 Nov 4. No abstract available.

25.

A Hyaluronidase-Responsive Nanoparticle-Based Drug Delivery System for Targeting Colon Cancer Cells.

Zhang M, Xu C, Wen L, Han MK, Xiao B, Zhou J, Zhang Y, Zhang Z, Viennois E, Merlin D.

Cancer Res. 2016 Dec 15;76(24):7208-7218. Epub 2016 Oct 14.

26.

Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease.

Si XY, Merlin D, Xiao B.

World J Gastroenterol. 2016 Sep 14;22(34):7718-26. doi: 10.3748/wjg.v22.i34.7718. Review.

27.

Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy.

Zhang M, Xiao B, Wang H, Han MK, Zhang Z, Viennois E, Xu C, Merlin D.

Mol Ther. 2016 Oct;24(10):1783-1796. doi: 10.1038/mt.2016.159. Epub 2016 Aug 5.

28.

Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.

Viennois E, Ingersoll SA, Ayyadurai S, Zhao Y, Wang L, Zhang M, Han MK, Garg P, Xiao B, Merlin D.

Cell Mol Gastroenterol Hepatol. 2016 May;2(3):340-357.

29.

Plant derived edible nanoparticles as a new therapeutic approach against diseases.

Zhang M, Viennois E, Xu C, Merlin D.

Tissue Barriers. 2016 Feb 11;4(2):e1134415. doi: 10.1080/21688370.2015.1134415. eCollection 2016 Apr-Jun. Review.

30.

Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.

Xiao B, Ma L, Merlin D.

Expert Opin Drug Deliv. 2017 Jan;14(1):65-73. Epub 2016 Jul 6. Review.

31.

Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer.

Zhang M, Viennois E, Prasad M, Zhang Y, Wang L, Zhang Z, Han MK, Xiao B, Xu C, Srinivasan S, Merlin D.

Biomaterials. 2016 Sep;101:321-40. doi: 10.1016/j.biomaterials.2016.06.018. Epub 2016 Jun 9.

32.

PepT1 Expression Helps Maintain Intestinal Homeostasis by Mediating the Differential Expression of miRNAs along the Crypt-Villus Axis.

Zhang Y, Viennois E, Zhang M, Xiao B, Han MK, Walter L, Garg P, Merlin D.

Sci Rep. 2016 Jun 1;6:27119. doi: 10.1038/srep27119.

33.

Minimally invasive screening for colitis using attenuated total internal reflectance fourier transform infrared spectroscopy.

Titus J, Viennois E, Merlin D, Unil Perera AG.

J Biophotonics. 2017 Mar;10(3):465-472. doi: 10.1002/jbio.201600041. Epub 2016 Apr 20.

34.

Urocanic acid-modified chitosan nanoparticles can confer anti-inflammatory effect by delivering CD98 siRNA to macrophages.

Xiao B, Ma P, Viennois E, Merlin D.

Colloids Surf B Biointerfaces. 2016 Jul 1;143:186-193. doi: 10.1016/j.colsurfb.2016.03.035. Epub 2016 Mar 14.

35.

Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy.

Xiao B, Si X, Han MK, Viennois E, Zhang M, Merlin D.

J Mater Chem B. 2015 Oct 21;3(39):7724-7733. Epub 2015 Sep 1.

36.

Glial cell line-derived neurotrophic factor protects against high-fat diet-induced hepatic steatosis by suppressing hepatic PPAR-γ expression.

Mwangi SM, Peng S, Nezami BG, Thorn N, Farris AB 3rd, Jain S, Laroui H, Merlin D, Anania F, Srinivasan S.

Am J Physiol Gastrointest Liver Physiol. 2016 Jan 15;310(2):G103-16. doi: 10.1152/ajpgi.00196.2015. Epub 2015 Nov 12.

37.

Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy.

Xiao B, Han MK, Viennois E, Wang L, Zhang M, Si X, Merlin D.

Nanoscale. 2015 Nov 14;7(42):17745-55. doi: 10.1039/c5nr04831a. Epub 2015 Oct 12.

38.

Proceedings of the Second Shanthi V. Sitaraman Intestinal Pathobiology Symposium.

Etienne-Mesmin L, Wang T, Viennois E, Chassaing B, Gewirtz AT, Merlin D.

Inflamm Bowel Dis. 2015 Aug;21(8):1942-7. doi: 10.1097/MIB.0000000000000528.

39.

Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy.

Xiao B, Si X, Zhang M, Merlin D.

Colloids Surf B Biointerfaces. 2015 Nov 1;135:379-85. doi: 10.1016/j.colsurfb.2015.07.081. Epub 2015 Aug 1.

40.

Microelectrode miRNA sensors enabled by enzymeless electrochemical signal amplification.

Wang T, Viennois E, Merlin D, Wang G.

Anal Chem. 2015 Aug 18;87(16):8173-80. doi: 10.1021/acs.analchem.5b00780. Epub 2015 Aug 4.

PMID:
26241158
41.

Granulocyte-Macrophage Colony-Stimulating Factor-Activated Monocytes as an Anti-inflammatory Player in the Intestine.

Viennois E, Merlin D.

Cell Mol Gastroenterol Hepatol. 2015 Jun 4;1(4):354-355. doi: 10.1016/j.jcmgh.2015.05.002. eCollection 2015 Jul. No abstract available.

42.

Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.

Viennois E, Zhao Y, Merlin D.

Inflamm Bowel Dis. 2015 Oct;21(10):2467-74. doi: 10.1097/MIB.0000000000000444. Review.

43.

Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles.

Xiao B, Zhang M, Viennois E, Zhang Y, Wei N, Baker MT, Jung Y, Merlin D.

Biomaterials. 2015 Apr;48:147-60. doi: 10.1016/j.biomaterials.2015.01.014. Epub 2015 Feb 11.

44.

A click-and-release approach to CO prodrugs.

Wang D, Viennois E, Ji K, Damera K, Draganov A, Zheng Y, Dai C, Merlin D, Wang B.

Chem Commun (Camb). 2014 Dec 28;50(100):15890-3. doi: 10.1039/c4cc07748b.

PMID:
25376496
45.

Longitudinal study of circulating protein biomarkers in inflammatory bowel disease.

Viennois E, Baker MT, Xiao B, Wang L, Laroui H, Merlin D.

J Proteomics. 2015 Jan 1;112:166-79. doi: 10.1016/j.jprot.2014.09.002. Epub 2014 Sep 16.

46.

Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer.

Viennois E, Xiao B, Ayyadurai S, Wang L, Wang PG, Zhang Q, Chen Y, Merlin D.

Lab Invest. 2014 Sep;94(9):950-65. doi: 10.1038/labinvest.2014.89. Epub 2014 Jul 28.

47.

A CRISPR-Cas system enhances envelope integrity mediating antibiotic resistance and inflammasome evasion.

Sampson TR, Napier BA, Schroeder MR, Louwen R, Zhao J, Chin CY, Ratner HK, Llewellyn AC, Jones CL, Laroui H, Merlin D, Zhou P, Endtz HP, Weiss DS.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11163-8. doi: 10.1073/pnas.1323025111. Epub 2014 Jul 14.

48.

Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis.

Laroui H, Viennois E, Xiao B, Canup BS, Geem D, Denning TL, Merlin D.

J Control Release. 2014 Jul 28;186:41-53. doi: 10.1016/j.jconrel.2014.04.046. Epub 2014 May 5.

49.

Glycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticle.

Xiao B, Yang Y, Viennois E, Zhang Y, Ayyadurai S, Baker M, Laroui H, Merlin D.

J Mater Chem B. 2014 Mar 21;2(11):1499-1508.

50.

Supplemental Content

Loading ...
Support Center